US 11,583,556 C1 (13,051st)
Modified cells and methods of therapy
Branden Moriarity, Shoreview, MN (US); Beau Webber, Coon Rapids, MN (US); Modassir Choudhry, New York, NY (US); R. Scott McIvor, St. Louis Park, MN (US); David Largaespada, Mounds View, MN (US); Steven A. Rosenberg, Potomac, MD (US); Douglas C. Palmer, North Bethesda, MD (US); and Nicholas P. Restifo, Chevy Chase, MD (US)
Filed by Regents of the University of Minnesota, Minneapolis, MN (US); Intima Bioscience, Inc., New York, NY (US); and The U.S.A., as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US)
Reexamination Request No. 90/019,313, Nov. 30, 2023.
Reexamination Certificate for Patent 11,583,556, issued Feb. 21, 2023, Appl. No. 17/003,081, Aug. 26, 2020.
Application 90/019,313 is a continuation of application No. 16/786,013, filed on Feb. 10, 2020, abandoned.
Application 16/786,013 is a continuation of application No. 15/256,086, filed on Sep. 2, 2016, granted, now 11,147,837.
Application 15/256,086 is a continuation of application No. 15/224,159, filed on Jul. 29, 2016, abandoned.
Claims priority of provisional application 62/199,905, filed on Jul. 31, 2015.
Claims priority of provisional application 62/232,983, filed on Sep. 25, 2015.
Claims priority of provisional application 62/286,206, filed on Jan. 22, 2016.
Claims priority of provisional application 62/295,670, filed on Feb. 16, 2016.
Claims priority of provisional application 62/330,464, filed on May 2, 2016.
Claims priority of provisional application 62/360,245, filed on Jul. 8, 2016.
Ex Parte Reexamination Certificate issued on Oct. 10, 2025.
Int. Cl. C07K 14/725 (2006.01); A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/32 (2025.01); A61K 40/41 (2025.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 9/96 (2006.01); C12N 15/113 (2010.01); C12N 15/87 (2006.01); C12N 15/90 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/32 (2025.01); A61K 40/418 (2025.01); C07K 14/4718 (2013.01); C07K 14/70503 (2013.01); C07K 14/7158 (2013.01); C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 9/96 (2013.01); C12N 15/113 (2013.01); C12N 15/907 (2013.01); A61K 2239/38 (2023.05); C12N 15/87 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01)]
AS A RESULT OF REEXAMINATION, IT HAS BEEN DETERMINED THAT:
Claims 1-8 are cancelled.
New claims 9 and 10 are added and determined to be patentable.
1. A method of treating cancer in a human subject, the method comprising:
administering to the human subject an effective amount of a pharmaceutical composition that comprises (i) a population of genetically modified human natural killer (NK) cells that comprise a genomic disruption in an endogenous cytokine inducible SH2-containing (CISH) gene that suppresses or eliminates expression of a cytokine inducible SH2-containing (CISH) protein encoded by said CISH gene; and (ii) a pharmaceutically acceptable carrier or excipient.
[ 9. A method of treating cancer in a human subject, the method comprising:
administering to the human subject an effective amount of a pharmaceutical composition that comprises (i) a population of genetically modified human natural killer (NK) cells that comprise a genomic disruption in an endogenous cytokine inducible SH2-containing (CISH) gene that suppresses or eliminates expression of a cytokine inducible SH2-containing (CISH) protein encoded by said CISH gene, wherein said genomic disruption is a nucleotide insertion or deletion in exon 2 or exon 3 of said CISH gene; and (ii) a pharmaceutically acceptable carrier or excipient.]
[ 10. A method of treating cancer in a human subject, the method comprising:
administering to the human subject an effective amount of a pharmaceutical composition that comprises (i) a population of genetically modified human natural killer (NK) cells that comprise a genomic disruption in an endogenous cytokine inducible SH2-containing (CISH) gene that suppresses or eliminates expression of a cytokine inducible SH2-containing (CISH) protein encoded by said CISH gene, wherein said genomic disruption is a nucleotide insertion or deletion in said CISH gene, and wherein said genomic disruption is generated using a guide RNA that binds a target sequence within exon 2 or exon 3 of said CISH gene.; and (ii) a pharmaceutically acceptable carrier or excipient.]